Trials / Completed
CompletedNCT00724698
Evaluation of Desloratadine When Used in Patients With Either Allergic Rhinitis or Chronic Idiopathic Urticaria
Post-marketing Surveillance of the Safety, Tolerability and Efficacy of Desloratadine Tablet Among Filipino Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 3,011 (actual)
- Sponsor
- Organon and Co · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
Eligible patients will be prescribed Desloratadine 1 tablet of 5 mg once daily. Patients will be asked to follow-up for a final visit after 14 days (Day 15) where the safety, tolerability and clinical efficacy will be measured.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Desloratadine | Desloratadine 5 mg once daily |
Timeline
- Start date
- 2005-10-01
- Primary completion
- 2007-12-01
- Completion
- 2007-12-01
- First posted
- 2008-07-29
- Last updated
- 2022-02-09
- Results posted
- 2009-07-17
Source: ClinicalTrials.gov record NCT00724698. Inclusion in this directory is not an endorsement.